J2P-MC-LXBD

A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study to evaluate the efficacy and safety of 3 dose levels of BID administered LY3556050 in Adult Participants with Diabetic Peripheral Neuropathic Pain.